• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

循环肿瘤 DNA 分析可实现儿科肾肿瘤在诊断时的分子特征分析。

Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis.

机构信息

SIREDO Oncology Center (Care, Innovation and research for children and AYA with cancer), Institut Curie, Paris, France.

INSERM U830, Laboratoire de Génétique et Biologie des Cancers, Research Center, Institut Curie, Paris, France.

出版信息

Int J Cancer. 2019 Jan 1;144(1):68-79. doi: 10.1002/ijc.31620. Epub 2018 Oct 26.

DOI:10.1002/ijc.31620
PMID:29923174
Abstract

Circulating tumor DNA (ctDNA) is a powerful tool for the molecular characterization of cancer. The most frequent pediatric kidney tumors (KT) are Wilms' tumors (WT), but other diagnoses may occur. According to the SIOP strategy, in most countries pediatric KT have a presumptive diagnosis of WT if they are clinically and radiologically compatible. The histologic confirmation is established after post-chemotherapy nephrectomy. Thus, there is a risk for a small fraction of patients to receive neoadjuvant chemotherapy that is not adapted to the disease. The aim of this work is to perform molecular diagnosis of pediatric KT by tumor genetic characterization based on the analysis of ctDNA. We analyzed ctDNA extracted from plasma samples of 18 pediatric patients with KT by whole-exome sequencing and compared the results to their matched tumor and germline DNA. Copy number alterations (CNAs) and single nucleotide variations (SNVs) were analyzed. We were able to detect tumor cell specific genetic alterations-CNAs, SNVs or both-in ctDNA in all patients except in one (for whom the plasma sample was obtained long after nephrectomy). These results open the door to new applications for the study of ctDNA with regards to the molecular diagnosis of KT, with a possibility of its usefulness for adapting the treatment early after diagnosis, but also for disease monitoring and follow up.

摘要

循环肿瘤 DNA(ctDNA)是用于癌症分子特征分析的强大工具。最常见的儿科肾脏肿瘤(KT)是肾母细胞瘤(WT),但也可能有其他诊断。根据 SIOP 策略,在大多数国家,如果儿科 KT 在临床和影像学上与 WT 相符,通常会假定为 WT 进行治疗。在化疗后进行肾切除术以明确组织学诊断。因此,一小部分患者可能会接受不适合疾病的新辅助化疗。本研究旨在通过基于 ctDNA 分析的肿瘤遗传特征对儿科 KT 进行分子诊断。我们通过全外显子组测序分析了来自 18 名儿科 KT 患者的血浆样本中的 ctDNA,并将结果与匹配的肿瘤和种系 DNA 进行比较。分析了拷贝数改变(CNAs)和单核苷酸变异(SNVs)。除了一名患者(其血浆样本是在肾切除术后很久采集的)外,我们能够在所有患者的 ctDNA 中检测到肿瘤细胞特异性遗传改变——CNA、SNV 或两者兼而有之。这些结果为研究 ctDNA 用于 KT 的分子诊断开辟了新的应用途径,有可能在诊断后早期对治疗进行调整,也有可能用于疾病监测和随访。

相似文献

1
Circulating tumor DNA analysis enables molecular characterization of pediatric renal tumors at diagnosis.循环肿瘤 DNA 分析可实现儿科肾肿瘤在诊断时的分子特征分析。
Int J Cancer. 2019 Jan 1;144(1):68-79. doi: 10.1002/ijc.31620. Epub 2018 Oct 26.
2
Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study.在国际儿科肿瘤学会(SIOP)WT 2001试验中,1q增益作为术前化疗治疗的肾母细胞瘤(WTs)的预后生物标志物:一项SIOP肾肿瘤生物学联盟研究。
J Clin Oncol. 2016 Sep 10;34(26):3195-203. doi: 10.1200/JCO.2015.66.0001. Epub 2016 Jul 18.
3
Preoperative diagnosis of clear cell sarcoma of the kidney by detection of BCOR internal tandem duplication in circulating tumor DNA.通过检测循环肿瘤 DNA 中的 BCOR 内部串联重复,术前诊断肾脏透明细胞肉瘤。
Genes Chromosomes Cancer. 2018 Oct;57(10):525-529. doi: 10.1002/gcc.22648. Epub 2018 Aug 20.
4
Comprehensive characterization of cell-free tumor DNA in plasma and urine of patients with renal tumors.肾肿瘤患者血浆和尿液中游离肿瘤DNA的综合特征分析。
Genome Med. 2020 Feb 28;12(1):23. doi: 10.1186/s13073-020-00723-8.
5
Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma.血浆循环肿瘤 DNA 与转移性肾细胞癌中的克隆性造血。
Clin Genitourin Cancer. 2020 Aug;18(4):322-331.e2. doi: 10.1016/j.clgc.2019.12.018. Epub 2020 Jan 8.
6
Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533.循环肿瘤 DNA 作为 III 期和 IV 期肾母细胞瘤患者的生物标志物:来自儿童肿瘤学组试验的分析,AREN0533。
J Clin Oncol. 2022 Sep 10;40(26):3047-3056. doi: 10.1200/JCO.22.00098. Epub 2022 May 17.
7
Evaluation of Renal Function in Pediatric Patients After Treatment for Wilms' Tumor.肾母细胞瘤治疗后小儿患者的肾功能评估
Adv Clin Exp Med. 2015 May-Jun;24(3):497-504. doi: 10.17219/acem/43768.
8
Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancer.在乳腺癌患者中,通过循环肿瘤 DNA 追踪纵向 HER2 扩增,以进行疗效监测和预后评估。
Breast. 2020 Feb;49:261-266. doi: 10.1016/j.breast.2019.12.010. Epub 2019 Dec 20.
9
A Comprehensive Circulating Tumor DNA Assay for Detection of Translocation and Copy-Number Changes in Pediatric Sarcomas.一种全面的循环肿瘤 DNA 检测方法,用于检测儿科肉瘤中的易位和拷贝数变化。
Mol Cancer Ther. 2021 Oct;20(10):2016-2025. doi: 10.1158/1535-7163.MCT-20-0987. Epub 2021 Aug 5.
10
The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.日本九州地区小儿实体瘤研究组关于初始切除的 Wilms 瘤中胚细胞瘤样组织学为主的预后意义的报告。
J Pediatr Surg. 2012 Dec;47(12):2205-9. doi: 10.1016/j.jpedsurg.2012.09.009.

引用本文的文献

1
Wilms' Tumor: A Review of Clinical Characteristics, Treatment Advances, and Research Opportunities.肾母细胞瘤:临床特征、治疗进展及研究机会综述
Medicina (Kaunas). 2025 Mar 12;61(3):491. doi: 10.3390/medicina61030491.
2
Paediatric renal tumours: an update on challenges and recent developments.小儿肾肿瘤:挑战与最新进展综述
Virchows Arch. 2025 Jan;486(1):49-64. doi: 10.1007/s00428-024-04017-x. Epub 2025 Jan 9.
3
A comprehensive overview of liquid biopsy applications in pediatric solid tumors.液体活检在儿科实体瘤中的应用综述
NPJ Precis Oncol. 2024 Aug 3;8(1):172. doi: 10.1038/s41698-024-00657-z.
4
Extracellular Vesicles for Childhood Cancer Liquid Biopsy.用于儿童癌症液体活检的细胞外囊泡
Cancers (Basel). 2024 Apr 26;16(9):1681. doi: 10.3390/cancers16091681.
5
Case series on clinical applications of liquid biopsy in pediatric solid tumors: towards improved diagnostics and disease monitoring.儿童实体瘤液体活检临床应用病例系列:迈向改进诊断和疾病监测
Front Oncol. 2023 Aug 17;13:1209150. doi: 10.3389/fonc.2023.1209150. eCollection 2023.
6
Biomarkers for patients with Wilms tumor: a review.肾母细胞瘤患者的生物标志物:综述
Front Oncol. 2023 Jul 24;13:1137346. doi: 10.3389/fonc.2023.1137346. eCollection 2023.
7
Circulating Cell-Free Tumor Deoxyribonucleic Acid Analysis as a Tool for the Diagnosis and Monitoring of Pediatric Solid Tumors.循环游离肿瘤脱氧核糖核酸分析作为小儿实体瘤诊断和监测的工具
Turk Arch Pediatr. 2023 May;58(3):241-249. doi: 10.5152/TurkArchPediatr.2023.23014.
8
Cell-Free DNA as a Diagnostic and Prognostic Biomarker in Pediatric Rhabdomyosarcoma.无细胞游离 DNA 作为儿科横纹肌肉瘤的诊断和预后生物标志物。
JCO Precis Oncol. 2023 Jan;7:e2200113. doi: 10.1200/PO.22.00113.
9
The potential key genes and pathways associated with Wilms tumor in quest of proper candidates for diagnostic and therapeutic purposes.探索与肾母细胞瘤相关的潜在关键基因和通路,以期为诊断和治疗寻找合适的候选靶点。
Sci Rep. 2022 Oct 25;12(1):17906. doi: 10.1038/s41598-022-22925-3.
10
An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma.尤因肉瘤分子生物标志物优先级的国际工作组共识报告。
NPJ Precis Oncol. 2022 Sep 17;6(1):65. doi: 10.1038/s41698-022-00307-2.